Orchard Therapeutics Plc Stock Price, News & Analysis

ORTX NASDAQ

Company Description

Orchard Therapeutics Plc (NASDAQ: ORTX) is a publicly traded research and development in biotechnology company in the Professional, Scientific, and Technical Services sector.

ORTX stock has declined 100.0% over the past year.

This page provides a comprehensive overview of ORTX stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

Chart

$—

0.00%

0.00

Last updated:

-100%

Performance 1 year

$0.0

Market Cap

22.8M

Shares outstanding

Orchard Therapeutics Plc (ORTX) stock. Over the past 12 months, the stock has lost 100.0%.

Latest News

View All

May 7, 2024

—

Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024

May 3, 2024

—

Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List

March 20, 2024

0.00%

Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy

March 18, 2024

0.00%

Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.

fda approval

February 5, 2024

-100.00%

Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome

February 2, 2024

0.00%

Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposium

Orchard Therapeutics Plc has 10 recent news articles. Of the recent coverage, 2 articles coincided with positive price movement and 1 with negative movement. Key topics include fda approval, acquisition, clinical trial. View all ORTX news →

SEC Filings

View All

No SEC filings available for ORTX.

Financial Highlights

View Full Financials

—

Revenue (TTM)

—

Net Income (TTM)

—

Diluted EPS (TTM)

—

Operating Cash Flow

—

Net Profit Margin

—

Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Days to Cover History

Last 12 Months

ORTX Company Profile & Sector Positioning

Orchard Therapeutics Plc (ORTX) operates in the Research and Development in Biotechnology industry within the broader Professional, Scientific, and Technical Services sector and is listed on the NASDAQ.